Date: 2014-06-24
Type of information: Development agreement
Compound: antibiotics targeting drug-resistant bacteria for community hospital-acquired infections
Company: Debiopharm (Switzerland) TCG Lifesciences (India)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease: community hospital-acquired infections
Details: * On September 9, 2013, Debiopharm Group and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, have announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections. Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program. TCGLS is a contract research services company in the area of early drug discovery and development. They started their operations in the year 2001 in India. Currently TCGLS is present in the United States, Europe, Japan and Australia. Their services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases.
Financial terms:
Latest news: * On June 24, 2014, Debiopharm and TCG Lifesciences announced that they have reached the first research milestone and consequently enter into lead optimization phase for innovative antibiotics targeting drug-resistant bacteria for community and hospital-acquired infections. This first step towards identification of new classes of targeted anti-infectious drugs was achieved only 9 months after signature of adiscovery collaboration will trigger the payment of research milestones by Debiopharm according to a pre-defined research plan. Andrés McAllister, Chief Scientific Officer, Debiopharm International SA, stated: "It is an important milestone for Debiopharm, supporting our strong commitment to develop novel antibiotics to overcome resistance to current treatments. It is part of our global strategy initiated with the development of our FabI inhibitors, Debio 1450, currently in clinical Phase I and Debio 1452 which has already demonstrated high efficacy in the treatment of acute bacterial skin and skin-structure infections in a phase II trial."
